-

Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17, 2022, in Dallas.

The annual Innovative Technology Exchange offers selected suppliers the opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

The Ivenix Infusion System from Fresenius Kabi is a large volume infusion pump supported by a management system specifically designed to simplify each step of infusion delivery and help eliminate unnecessary work while informing patient care teams.

To meaningfully impact medication safety, we reimagined the infusion process from beginning to end,” said Susan Niemeier, vice president, clinical excellence and product strategy for infusion systems at Fresenius Kabi. “Every aspect of the Ivenix Infusion System is designed to improve outcomes, prevent infusion-related errors and elevate the clinician experience. We look forward to sharing the Ivenix Infusion System with the participants of the Vizient Innovative Technology Exchange in October and demonstrating how we can transform infusion delivery together.”

“Suppliers apply to attend the Exchange hoping their product will be awarded an Innovative Technology contract, which signals health care providers of their product’s unique qualities,” said Kelly Flaharty, senior director of contract services, Vizient. “The selection process for suppliers who exhibit at the Exchange is rigorous, and this technology has earned its coveted invitation to the event.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product reviews of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed more than 1,600 product submissions as part of its Innovative Technology Program.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has been certified by the Top Employers Institute as a 2026 Top Employer in the United States and North America. This affirms the company’s ongoing commitment to creating a positive work environment. Globally, Fresenius Kabi was certified as a Top Employer for 2026 in 13 countries and two regions. Since 2023, Fre...

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing. Frese...

Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® (ustekinumab-aauz) in a 45 mg/0.5 mL single-dose vial for subcutaneous injection. Otulfi® is a prescription medicine and the brand name for Fresenius Kabi’s FDA-approved biosimilar of the reference product, Stelara® (ustekinumab). With this addition, Fresenius Kabi now offers...
Back to Newsroom